ストックスクリーナーアプリを入手
14.11
2.47%
0.34
プレマーケット:
13.81
-0.30
-2.13%
前日終値:
$13.77
開ける：
$13.88
24時間の取引高:
342.04K
Relative Volume:
0.64
時価総額：
$758.72M
収益：
$217.25M
当期純損益:
$-50.92M
株価収益率:
-14.11
EPS:
-1
ネットキャッシュフロー:
$-100.85M
1週間 パフォーマンス:
+11.37%
1か月 パフォーマンス:
-7.29%
6か月 パフォーマンス:
-40.16%
1年 パフォーマンス:
-57.31%
1日の値動き範囲:
$13.79
$14.26
1週間の範囲:
$12.89
$14.40
52週間の値動き範囲:
$11.70
$34.75
Prothena Corporation Plc Stock (PRTA) Company Profile
名前
Prothena Corporation Plc
セクター
電話
011-353-1-236-2500
住所
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
PRTA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
14.11 | 758.72M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-01-30 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-04-24 | 開始されました | SVB Securities | Outperform |
| 2023-01-27 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-11-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-06-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Oppenheimer | Outperform |
| 2021-05-26 | 開始されました | Citigroup | Buy |
| 2021-02-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-12-07 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-05-21 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-04-23 | ダウングレード | Jefferies | Buy → Hold |
| 2018-04-05 | 繰り返されました | Barclays | Overweight |
| 2017-11-20 | ダウングレード | Wedbush | Outperform → Neutral |
| 2017-09-29 | 繰り返されました | BTIG Research | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Jefferies | Buy |
| 2017-04-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2016-12-21 | 開始されました | SunTrust | Buy |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-08-04 | 繰り返されました | Barclays | Overweight |
| 2016-05-13 | 開始されました | Barclays | Overweight |
| 2016-02-19 | 繰り返されました | Wedbush | Outperform |
| 2016-01-21 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Prothena Corporation Plc (PRTA) 最新ニュース
JPMorgan Chase & Co. Lowers Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
JPMorgan Chase & Co. Has $3.35 Million Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Hennion & Walsh Asset Management Inc. Buys Shares of 52,284 Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Shares Up 6.8%Time to Buy? - MarketBeat
Trading (PRTA) With Integrated Risk Controls - Stock Traders Daily
Barclays PLC Grows Stock Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Purchased by Barclays PLC - Defense World
Prothena (NASDAQ:PRTA) Stock Price Down 9%Here's What Happened - MarketBeat
Prothena (NASDAQ:PRTA) Trading Up 6.5%What's Next? - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $52.29 Average Price Target from Analysts - Defense World
Prothena Corporation plc (NASDAQ: PRTA) Down -6.92%: Here’s What Analysts’ Predictions Are Now. - Stocks Register
Brokerages Set Prothena Co. plc (NASDAQ:PRTA) Price Target at $52.29 - MarketBeat
Prothena (NASDAQ:PRTA) Trading Down 2.6%Time to Sell? - MarketBeat
Prothena Corporation PLC (NASDAQ:PRTA) Director Oleg Nodelman Resigns - Defense World
Prothena Director Oleg Nodelman Steps Down After 5-Year Tenure, Ahead of Major 2025 Clinical Milestones - StockTitan
Prothena Co. plc (NASDAQ:PRTA) Shares Sold by Geode Capital Management LLC - Defense World
Prothena Co. plc (NASDAQ:PRTA) Shares Bought by Barclays PLC - Defense World
Barclays PLC Buys 49,916 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
How the (PRTA) price action is used to our Advantage - Stock Traders Daily
We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate - Yahoo Finance
Prothena Co. plc (NASDAQ:PRTA) Position Trimmed by State Street Corp - Defense World
Prothena Co. plc (NASDAQ:PRTA) Holdings Decreased by State Street Corp - MarketBeat
Prothena Surges After Parkinson's Drug Misses Primary Endpoint - Seeking Alpha
Prothena (NASDAQ:PRTA) Earns Buy Rating from HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Coverage Initiated at Chardan Capital - MarketBeat
Demystifying Prothena Corp: Insights From 6 Analyst Reviews - Benzinga
Even after rising 16% this past week, Prothena (NASDAQ:PRTA) shareholders are still down 67% over the past three years - Simply Wall St
Prothena Corp (NASDAQ:PRTA) Stock Quotes, Forecast and News Summary - Benzinga
Prothena Shares Surge 43% Despite Setback in Parkinson's Drug Trial, Investors Eye Future Potential - mediahousepress
Prothena stock soars despite study miss By Investing.com - Investing.com Canada
Prothena stock soars despite study miss - Investing.com
Prothena (NASDAQ:PRTA) Price Target Cut to $22.00 by Analysts at Bank of America - MarketBeat
Why Is Prothena Corp Stock Soaring Today?Roche Holding (OTC:RHHBY) - Benzinga
Prothena shares price target cut after Parkinson's study miss By Investing.com - Investing.com UK
Prothena stock gains despite Parkinson’s setback (RHHBY:OTCQX) - Seeking Alpha
Prothena’s Parkinson’s study fails primary endpoint despite some success - Yahoo Finance
Prothena (NASDAQ:PRTA) Hits New 52-Week LowHere's Why - MarketBeat
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease - Business Wire
Prothena (NASDAQ:PRTA) Stock Price Down 3.6%Should You Sell? - MarketBeat
Prothena (NASDAQ:PRTA) Stock Price Up 7.8%What's Next? - MarketBeat
Where are the Opportunities in (PRTA) - Stock Traders Daily
Prothena's SWOT analysis: biotech stock's high-risk, high-reward pipeline - Investing.com
Oppenheimer bullish on Prothena stock, sees $1B opportunity for birtamimab in rare disease - Investing.com Nigeria
Janus Henderson Group PLC Sells 1,008,511 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Reaches New 1-Year LowWhat's Next? - MarketBeat
Charles Schwab Investment Management Inc. Decreases Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? - Yahoo Finance
Wellington Management Group LLP Has $69.91 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
FY2024 EPS Estimates for Prothena Increased by Analyst - MarketBeat
Systematic Financial Management LP Sells 185,638 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Corporation Plc (PRTA) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):